Developement of anti- P. aeruginosa Immunoglobulin Y antibodies as prophylacic therapy for cystic fibrosis patients

Manal M. E. Ahmed¹ , Jakeen Eljakee² , Tarek Mahran³

Section:Research Paper, Product Type: Journal-Paper
Vol.7 , Issue.2 , pp.44-50, Apr-2020

Online published on Apr 30, 2020

Copyright © Manal M. E. Ahmed, Jakeen Eljakee, Tarek Mahran . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

Abstract :
Emergence of multidrug-resistance (MDR) P. aeruginosa for respiratory tract infections represents a major critical challenge to the health care community worldwide. It is associated with progressive chronic respiratory infection in patients with cystic fibrosis (CF). While, the antibiotic resistance has been a global growing problem and vaccines development is impeded by several limitations, an urgent need to develop novel approaches is growing. In this study, we developed anti- P. aeruginosa IgYs as an alternative to meet this need. Preclinical evaluation revealed that immunization of Balb/c mice with the developed IgYs resulted in 95%, 90%, 70% protective effect among group (A) that was immunized intranasal one hour before challenge, group (B) that was immunized intranasal six hours after challenge and group (C) that was immunized orally, respectively. Furthermore, the pulmonary bacterial load in treated mice was lower than in the controls by more than 2 log after 24 hours of infection. Thus, the prepared IgYs had anti-P. aeruginosa immuno-reactivity that increasing its potential for use as a prophylactic therapy.

Key-Words / Index Term :
P. Aeruginosa, Immunoglobulins Y, Cystic fibrosis, protective efficacy, challenge test, prophylactic therapy

References :
[1] P.B. Davis, M. Drumm, M.W. Konstan, "Cystic fibrosis", Am. J. Respir. Crit. Care Med, Vol. 154, Issue. 5, pp. 1229–1256, 1996.
[2] P.H. Gilligan, "Microbiology of airway disease in patients with cystic fibrosis", J Clin Microbiol, Vol. 4, pp. 35–51, 1991.
[3] U.B. Schaad, A.B. Lang, J. Wedgwood, A. Ruedeberg, J.U. Que, E. Furer, S.J.J. Cryz, "Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis", Lancet , Vol. 338, pp. 1236–1237, 1991.
[4] J.J. Smith, S.M. Travis, E.P. Greenberg, M.J. Welsh, "Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid", Cell, Vol. 85, pp. 229–236, 1996.
[5] J.L. McCaskill, S. Ressel, A. Alber, J. Redford, U.F. Power, J. Schwarze, B.M. Dutia, A.H. Buck, "Broad-spectrum inhibition of respiratory virus infection by MicroRNA mimics targeting p38 MAPK signaling", Mol Ther Nucl Acids, Vol. 7, pp. 256–266, 2017.
[6] D. Corti, N. Passini, A. Lanzavecchia, M. Zambon, "Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome", J Infect Public Health , Vol. 9, pp. 231–235, 2016.
[7] A.W. Cripps, M.L. Dunkley, R.L. Clancy, J. Kyd, "Pulmonary immunity to Pseudomonas aeruginosa", Immunol Cell Biol, Vol. 73, pp. 418–424, 1995.
[8] M.A. Keller, E.R. Stiehm, "Passive immunity in prevention and treatment of infectious diseases", Clin Microbiol Rev, Vol. 13, pp. 602-614, 2000.
[9] B.S. Gaham, D.M. Ambrosino, "History of passive antibody administration for prevention and treatment of infectious diseases", Curr Opin HIV AIDS. Vol. 10, pp. 129–134, 2015.
[10] B. Kelley, "Industrialization of mAb production technology: the bioprocessing industry at a crossroads", mAbs, Vol. 1, pp. 443–452, 2009.
[11] A. Casadevall, E. Dadachova, L.A. Pirofski, "Passive antibody therapy for infectious diseases", Nat Rev Microbiol, Vol. 2, pp. 695–703, 2004.
[12] G.W. Warr, K.E. Magor, D.A. Higgins, "IgY: clues to the origins of modern antibodies", Immunol Today, Vol. 16, pp. 392–398, 1995.
[13] D. Carlander, J. Stalberg, A. Larsso, "Chicken antibodies: a clinical chemistry perspective", Ups J Med Sci, Vol. 104, pp. 179–189, 1999.
[14] K. Thomsen, L. Christophersen, T. Bjarnsholt, P.O. Jensen, C. Moser, N. Hoiby, "Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model", J Cyst Fibr, Vol. 15, pp. 171-178, 2016.
[15] H.H. Nguyen, T.M. Tumpey, H. J. Park, Y.H. Byun, L.D. Tran, V.D. Nguyen, P.E. Kilgore, C. Czerkinsky, J.M. Katz, B.L. Seong, J.M. Song, Y.B. Kim, H.T. Do, T. Nguyen, C.V. Nguyen, "Prophylactic and therapeutic efficacy of avian antibodies against Influenza virus H5N1 and H1N1 in mice", PLoS One, Vol. 5, pp. e10152, 2010.
[16] E.M. Akita, S. Nakai, "Comparison of four purification methods for the production of immunoglobulins from eggs laid by hens immunized with an enterotoxigenic E. coli strain.", J Immunol Methods, Vol. 160, pp. 207-214, 1993.
[17] R. Chalghoumi, A. Thewis, Y. Beckers, C. Marcq, D. Portetelle, Y.J. Schneider, "Adhesion and growth inhibitory effect of chicken egg yolk antibody (IgY) on Salmonella enterica serovars Enteritidis and Typhimurium in vitro", Food borne Pathog Dis, Vol. 6, pp. 593-604, 2009.
[18] M. Kuroki, Y. Ikemori, H. Yokoyama, R.C. Peralta, F.C. Icatlo, Y. Kodama, "Passive protection against bovine rotavirus-induced diarrhea in murine model by specific immunoglobulins from chicken egg yolk.", Vet Microbiol, Vol. 37, pp. 135-146, 1993.
[19] P.H. Gilligan, "Infections in patients with cystic fibrosis: diagnostic microbiology update. Clinics in Laboratory Medicine", Vol. 34, Issue. 2, pp. 197–217, 2014.
[20] N. Safdar, C. Dezfulian, H.R. Collard, S. Saint, "Clinical and economic consequences of ventilator-associated pneumonia: a systematic review", Critical Care Medicine, Vol. 33, Issue. 10, pp. 2184–2193, 2005.
[21] B.K Chan., M. Sistrom, J.E. Wertz, K.E. Kortright, D. Narayan, P.E. Turner, "Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa", Scientific Reports , Vol. 6, pp. 26717, 2016.
[22] M.W. Douglas, K. Mulholland, V. Denyer, T. Gottlieb, "Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unit—an infection control study", Burns: Journal of the International Society for Burn. Injuries, Vol. 27, Issue. 2, pp. 131–135, 2001.
[23] M. Mudau , R. Jacobson, N. Minenza, L. Kuonza, V. Morris, H. Engelbrecht, M.P. Nicol, C. Bamford, "Outbreak of multidrug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African academic hospital", PLoS One, Vol. 8, Issue. 3, pp. e55985, 2013.
[24] G.P. Priebe, G.J. Meluleni, F.T. Coleman, J.B. Goldberg, G.B. Pier, "Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant", Infect. Immun, Vol. 71, pp. 1453–1461, 2003.
[25] J. Kovacs-Nolan, Y. Mine. "Egg yolk antibodies for passive immunity", Annu Rev Food Sci Technol, Vol. 3, pp. 163–182, 2012.
[26] R. Weltzin, T.P. Monath, "Intranasal antibody prophylaxis for protection against viral disease", Clin Microbiol Rev, Vol. 12, pp. 383–393, 1999.
[27] R. Schade, A. Hlinak, "Egg yolk antibodies, state of the art and future prospects", Altex, Vol. 13, pp. 5–9, 1996.
[28] K. Selvan, R. Sentila, . A. Michael, "eneration and characterization of chicken egg yolk antibodies against propionibacterium acnes for the prevention of acne vulgaris", Indian J Dermatol, Vol. 57, pp. 15–19, 2012.
[29] El S.M. Ibrahim, A.K. Rahman, R. Isoda, K. Umeda, N. Van Sa, Y. Kodama", In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY)", Vaccine, Vol. 26, pp. 2073–2080, 2008.
[30] S.V. Nguyen, F.C. Jr. Icatlo, T. Nakano, E. Isogai, K. Hirose, H. Mizugai, M. Kobayashi-Sakamoto, H. Isogai, I. Chiba, "Anti-cell-associated glucosyl transferase immunoglobulin Y suppression of salivary mutans streptococci in healthy young adults", J Am Dent Assoc, Vol. 142, pp. 943–949, 2011.
[31] K. Yokoyama, N. Sugano, T. Shimada, R.A.K.M. Shofiqur, El. S.M. Ibrahim, R. Isoda, K. Umeda, N.V. Sa, Y. Kodama, K. Ito, "Effects of egg yolk antibody against Porphyromonas gingivalis gingipains in periodontitis patients", J Oral Sci, Vol. 49, pp. 201–206, 2007.
[32] H. Suzuki, S. Nomura , T. Masaoka, H. Goshima, N. Kamata, Y. Kodama, H. Ishii, M. Kitajima, K. Nomoto, T. Hibi, "Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection", Aliment Pharmacol Ther, Vol. 20, Issue. Suppl 1, pp. 185–192, 2004.
[33] K.S. Hong, M.R. Ki, H.M.A. Ullah, E.J. Lee, Y.D. Kim, M.J. Chung, A.K. Elfadl, J.K. Park, K.S. Jeong , "Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice", Vaccine, Vol. 36, pp. 371–380, 2018.
[34] N. Gujral, R. Lobenberg, M. Suresh, H. Sunwoo, "In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix", J Agric Food Chem, Vol. 60, pp. 3166–3172, 2012.
[35] K. Hirai, H. Arimitsu, K. Umeda, K. Yokota, L. Shen, K. Ayada, Y. Kodama, T. Tsuji, Y. Hirai, K. Oguma, "Passive oral immunization by egg yolk immunoglobulin (IgY) to Vibrio cholerae effectively prevents cholera", Acta Med Okayama , Vol. 64, pp. 163–170, 2010.
[36] S. Rahman, K. Higo-Moriguchi, K.W. Htun, K. Taniguchi, F.C. Icatlo, T. Tsuji, Y. Kodama, S. Van Nguyen, K. Umeda, H. N. Oo, et al.,"Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients`, Vaccine, Vol. 30, pp. 4661–4669, 2012.
[37] M. Hirose, T. Ando, R. Shofiqur, K. Umeda, Y. Kodama, S. Nguyen, T. Goto, M. Shimada, S. Nagaoka, "Anti-obesity activity of hen egg anti lipase immunoglobulin yolk, a novel pancreatic lipase inhibitor", Nutr Metab (Lond), Vol. 10, Issue. 1, pp. 70, 2013.
[38] A.T. Abbas, S.A. El-Kafrawy, S.S. Sohrab, E.I.A. Azhar, "EIA. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections`, Human Vaccines & Immunotherapeutics, Vol. 15, Issue. 1, pp. 264-275, 2019.
[39] J. Emerson, M. Rosenfeld, S. McNamara, B. Ramsey, R.L. Gibson, "Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis", Pediatr Pulmonol, Vol. 34, pp. 91–100, 2002.
[40] G.M. Nixon, D.S. Armstrong, R. Carzino, J. B. Carlin, A. Olinsky , C.F. Robertson, K. Grimwood, "Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis", J Pediatr, Vol. 138, pp. 699–704, 2001.
[41] E. Nilsson, A. Larsson, H.V. Olesen, P.E. Wejaker, H. Kollberg, "Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients", Pediatr Pulmonol, Vol. 43, pp. 892–899, 2008.
[42] M.M.E. Ahmed, W. Nazmy, J. Eljakee, "Preparation and Evaluation of Novel Anti-Obesity Immunoglobulins for Immunoprophylaxis and Therapy", International Journal of Scientific Research in Biological Sciences, Vol.6, Issue.6, pp.81-88, (2019).
[43] A.M. Abdou, M.M.E. Ahmed, Y. Yamashita, M. Kim, "Immunoglobulin: A Natural Way to Suppress Helicobacter pylori in Humans", Health, Vol.6, pp.781-791, 2014.